Akeega (niraparib;abiraterone acetate)
- Region
- 🇪🇺 EU
- Active substance
- niraparib;abiraterone acetate
- Status
- Authorised
- Therapeutic area
- Prostatic Neoplasms, Castration-Resistant
- CHMP opinion
- Thu 23 Feb 2023
- EU approval
- Wed 19 Apr 2023
- Application
- EMEA/H/C/005932
- ATC
- L01
- Official record
- www.ema.europa.eu
Indication
Treatment of adult patients with prostate cancer.
Regulatory milestones
No milestones recorded in the last year.
Follow Akeega
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.